Pharmacogenomic data for personalized medicines
Yamazaki, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(12): 1886-1890
2005
ISSN/ISBN: 0385-0684 PMID: 16282721 Document Number: 585670
FDA issued guidance for industry regarding pharmarcogenomic data submission this year. Polymorphic cytochrome P450 2D6 and thiopurine S-methyltransferase in patients are now considered biomarkers for drugs which are predominantly metabolized by these enzymes. This article reviews current efforts to treat pharmacogenomic data for new drug development and personalized medicines.
Document emailed within 1 workday
Related Documents
Coghlan, R.; Stephens, P.; Mwale, B.; Siyanga, M. 2018: A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia Malaria Journal 17(1): 444Lisitsyn, V.I. 2010: The analysis of mortality according the personalized data base of deceased population Problemy Sotsial'noi Gigieny Zdravookhraneniia i Istorii Meditsiny 6: 11-14
Kyriazis, D.; Autexier, S.; Brondino, I.án.; Boniface, M.; Donat, L.; Engen, V.; Fernandez, R.; Jimenez-Peris, R.; Jordan, B.; Jurak, G.; Kiourtis, A.; Kosmidis, T.; Lustrek, M.; Maglogiannis, I.; Mantas, J.; Martinez, A.; Mavrogiorgou, A.; Menychtas, A.; Montandon, L.; Nechifor, C.-S.; Nifakos, S.; Papageorgiou, A.; Patino-Martinez, M.; Perez, M.; Plagianakos, V.; Stanimirovic, D.; Starc, G.; Tomson, T.; Torelli, F.; Traver-Salcedo, V.; Vassilacopoulos, G.; Wajid, U. 2017: CrowdHEALTH: Holistic Health Records and Big Data Analytics for Health Policy Making and Personalized Health Studies in Health Technology and Informatics 238: 19-23
Pijpers, E.L.; Kreijkamp-Kaspers, S.; McGuire, T.M.; Deckx, L.; Brodribb, W.; van Driel, M.L. 2017: Women's questions about medicines in pregnancy - An analysis of calls to an Australian national medicines call centre Australian and New Zealand Journal of Obstetrics and Gynaecology 57(3): 334-341
Orubu, E.Samuel.F.; Okwelogu, C.; Opanuga, O.; Nunn, T.; Tuleu, C. 2016: Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development Health Policy and Planning (): -
Christophe, B.; Clouet, F.; Gillet, A.; Harf, R. 2003: Consumption of allergy medicines in 2000 and 2001: data from 12 Primary Medical Insurance Offices (CPAM) in the Rhône-Alpes region European Annals of Allergy and Clinical Immunology 35(5): 154-157
Crowley, J.J.; Sullivan, P.F.; McLeod, H.L. 2008: Untapped resources for pharmacogenomic discovery in psychiatry Current Opinion in Molecular Therapeutics 10(3): 205-206
Jonas, D.E.; Wines, R. 2013: Pharmacogenomic testing and the prospect of individualized treatment North Carolina Medical Journal 74(6): 485-493
Bai, H.; Ning, K.; Wang, C.-y. 2015: Biological ingredient analysis of traditional Chinese medicines utilizing metagenomic approach based on high-throughput-sequencing and big-data-mining Yao Xue Xue Bao 50(3): 272-277
Beer, A.M.; Schilcher, H.; Loew, D. 2013: Herbal medicines alternative to synthetical medicines MMW Fortschritte der Medizin 155(Suppl 4): 97-99
Adam, G.I. 2001: The development of pharmacogenomic models to predict drug response Current Opinion in Drug Discovery and Development 4(3): 296-300
Gini, J.; Amara, A.; Penchala, S.D.; Back, D.J.; Else, L.; Egan, D.; Chiong, J.; Harri, B.I.; Kabilis, E.D.; Pama, P.P.; Stephen, M.; Khoo, S.H. 2019: Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria International Journal of Std and Aids 30(4): 371-377
Wang, H.; Zhang, X-Bo.; Huang, L-Qi.; Guo, L-Ping.; Wang, L.; Zhao, Y-Ping.; Yang, G. 2017: Design and implementation of supply security monitoring and analysis system for Chinese patent medicines supply in national essential medicines Zhongguo Zhong Yao Za Zhi 42(22): 4310-4313
Joshua, I.B.; Passmore, P.R.; Sunderland, B.V. 2016: An evaluation of the Essential Medicines List, Standard Treatment Guidelines and prescribing restrictions, as an integrated strategy to enhance quality, efficacy and safety of and improve access to essential medicines in Papua New Guinea Health Policy and Planning 31(4): 538-546
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Goetz, P. 2009: The use of personalized genomic comprehensions Casopis Lekaru Ceskych 148(7): 295
Tokui, T. 2013: Translational research - towards personalized medicine Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(3): 122-125
Katsuya, T.; Rakugi, H. 2008: Potential of personalized antihypertensive therapy Nihon Rinsho. Japanese Journal of Clinical Medicine 66(8): 1583-1590
Iglesias, D.A.; Bodurka, D.C. 2012: Personalized care in uterine cancer Clinical Advances in Hematology and Oncology: H&o 10(12): 797-805
Kadia, T.M. 2016: Personalized treatment for patients with myelofibrosis Clinical Advances in Hematology and Oncology: H&o 14(6): 400-403